Schering probe
This article was originally published in The Tan Sheet
Executive Summary
Antitrust division of U.S. Justice Department in February "served a grand jury subpoena on the company seeking documents for the first time" about whether firm's consumer products division entered into an agreement with Wyeth "to lower the commission rate of a consumer products broker," firm says. In March 10 10-K filing with SEC Schering said it is "cooperating with the investigation." Wyeth announced DoJ probe last month (1"The Tan Sheet" Feb. 17, 2003, In Brief)...
You may also be interested in...
Wyeth DoJ probe
Firm "expects to receive a subpoena in the near future" for Department of Justice inquiry "into allegations of collusive practices" with another drug company, Wyeth states in Feb. 11 SEC filing. Case has been referred to a grand jury, Wyeth says. Allegations refer to collusion "relating to commission rates for a sales broker for a small segment of the" firm's OTC business, filing notes, although Wyeth maintains "our practices regarding brokers have not violated the antitrust laws." Schering-Plough disclosed a similar investigation in November. DoJ initiated the inquiry following same-day move by the two firms to reduce fees to Compass Marketing (1"The Tan Sheet" Aug. 19, 2002, In Brief)...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.